

Childhood Cancer Fact Library 2021

All statistics below are for U.S. children from birth through age 19 unless stated otherwise. This summary relies on the most recent published data with respect to its contents, some of which dates back one or more years.

Diagnosis

- Childhood cancer is not one disease - there are more than 12 major types of pediatric cancers and over 100 subtypes. ⁽¹⁾
- In 2022, it is estimated 10,470 children (birth to 14 years) and 5,480 adolescents (aged 15-19 years) will be diagnosed with cancer. ^(1a)
- The overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975. Children (0-14) increased 0.8%, and adolescents also increased 0.8%. Overall cancer incidence rates increased an average of 1% per year from 1997 to 2018. ^(45A)
- In 2021, there were approximately 88,260 cancer cases diagnosed and about 9,130 cancer deaths in adolescents and young adults (AYAs) ages 15 to 39 years in the US. ⁽⁴⁰⁾
- About 1 in 285 children will develop cancer before the age of 20. ^(6a)
- Children with Down syndrome are 10 to 20 times more likely to develop leukemia than children without Down syndrome. ⁽³⁷⁾
- 47 children per day or 17,293 children (aged 0-19) were diagnosed with cancer in 2018. ⁽⁴⁵⁾
- As of 2018, 4,317 children and teens under age 20 were diagnosed with CNS tumors, accounting for 25% of total cancer diagnoses in the age group 0-19. ⁽⁴⁵⁾
- The average age at diagnosis is 10 overall (ages 0 to 19), 6 years old for children (aged 0 to 14), and 17 years old for adolescents (aged 15 to 19) ⁽⁹⁾, while adults' median age for cancer diagnosis is 66 ^(7a)
- Most new cancer diagnoses in children are for leukemia (28.1%) and brain/CNS cancers (26.5%), while malignant epithelial neoplasms and melanomas (23.3%) and brain/CNS cancers (21.9%) are top cancers for adolescents. ⁽⁴⁵⁾

Long Term Health-Effects Associated with Treatments & Survival

- Cancer in children and young adults is different from cancer that develops later in life. Some of the unwanted side effects of cancer treatments cause more harm to children than they do to adults. This is because children's bodies are still growing and developing, so cancer and its treatment are more likely to affect developing organs. ^(7H)
- More than 95% of childhood cancer survivors will have a significant health related issue by the time they are 45 years of age ⁽²⁾; these health related issues are side-effects of either the cancer or more commonly, the result of its treatment. 1/3rd will suffer severe and chronic side effects; 1/3rd will suffer moderate to severe health problems; and 1/3rd will suffer slight to moderate side effects. ⁽²⁾
- Cognitive impairment affects up to one-third of childhood cancer survivors. ⁽³⁸⁾
- A large follow-up study of pediatric cancer survivors found that almost 10% developed a second cancer (most commonly female breast, thyroid, and bone) over the 30-year period after the initial diagnosis. ⁽³⁸⁾
- Treatment for cancer may cause infertility in childhood cancer survivors. The risk of infertility increases after treatment with chemotherapy with alkylating agents, such as cisplatin, cyclophosphamide, busulfan, lomustine, and procarbazine. ⁽³⁹⁾
- Female childhood cancer survivors who were treated with chemotherapy— even if they did not receive radiation treatments to their chest — are six times more likely than the general population to be diagnosed with breast cancer later in life. For those who did receive chest radiation, that chance increases exponentially and is on par with those who have the BRCA1 or BRCA2 mutations. ⁽²⁸⁾
- Childhood cancer survivors are at a 15-fold increased risk of developing Congestive Heart Failure and are at 7-fold higher risk of premature death due to cardiac causes, when compared with the general population. There is a strong dose-dependent relation between anthracycline chemotherapy exposure and CHF risk, and the risk is higher among those exposed to chest radiation. ⁽³³⁾
- Children who were treated for bone cancer, brain tumors, and Hodgkin lymphoma, or who received radiation to their chest, abdomen, or pelvis, have the highest risk of serious late effects from their cancer treatment, including second cancers, joint replacement, hearing loss, and congestive heart failure. ⁽⁴⁾

- Life expectancy for five -year childhood cancer survivors has steadily increased. Life expectancy for those treated in the 70's is only 48.5 years and survivors treated in the 80's have a life expectancy of 53.7 years, while those treated in the 90's rose to 57.1 years. ⁽⁴¹⁾ Normal life expectancy for adults is 80. ⁽¹³⁾
- Nearly a quarter of childhood cancer survivors experience at least one debilitating neuromuscular condition 20 years post diagnosis. ⁽⁴⁷⁾

Treatment, Research, Funding

- On average, in 2009 pediatric hospitalizations principally for cancer were 8 days longer and cost nearly 5 times as much as hospitalizations for other conditions (12.0 days versus 3.8 days; \$40,400 versus \$8,100 per stay). Costs per day were about 70 percent higher for pediatric cancer stays (\$3,900 versus \$2,300 per day). ⁽⁵⁾
- In 2009, pediatric stays principally for cancer cost nearly one billion dollars, accounting for over 5 percent of pediatric non-newborn inpatient hospital costs. ⁽⁵⁾
- One in four families lose more than 40% of their annual household income as a result of childhood cancer treatment-related work disruption, while one in three families face other work disruptions such as having to quit work or change jobs. ⁽³⁶⁾
- 1 in 5 CHILDREN who receive a new diagnosis of childhood cancer are already living in poverty. ⁽³⁶⁾
- Parents of long-term childhood cancer survivors reported lower household income and higher risk-of-poverty. In a study group of 769 parents of long-term childhood cancer survivors, 30.4% reported lower household income and were at higher risk-of-poverty. ^(36a)
- More than 90% of children and adolescents who are diagnosed with cancer each year in the United States are cared for at a children's cancer center that is affiliated with the NCI-supported Children's Oncology Group (COG). Children's Oncology Group is the world's largest organization that performs clinical research to improve the care and treatment of children and adolescents with cancer. Each year, approximately 4,000 children who are diagnosed with cancer enroll in a COG-sponsored clinical trial. COG trials are sometimes open to individuals aged 29 years or even older when the type of cancer being studied is one that occurs in children, adolescents, and young adults. ⁽⁴⁾
- As reflected below in the National Cancer Institute's (NCI) Funded Research Portfolio, from 2008 through 2018, the NCI spent an average of 4.08% of its research funding on childhood cancers research. ^(7C)

Funding

There are two conflicting reporting methods available that are used to gauge federal childhood cancer research investment. A report used in the past and often cited by advocates, is the National Cancer Institute's Funded Research Portfolio (NFRP)^(7C) below. It indicates that from 2008 through 2018, the NCI spent an average of 4.08% of its obligations on childhood cancer research. According to NCI's Office of Advocacy Relations (OAR), the NFRP *does not* reflect NCI's *total* investment in any one particular area of research—including childhood cancers—because it does not account for basic science awards, which are not categorized by cancer type and which may have applications to multiple types of cancer.

NCI Childhood Cancers Research Investment*			
Year	Total Budget NCI Funding	Childhood Cancers Funding	Percent
2008	\$4,827,552,152	\$189,672,374	3.93%
2009	\$4,966,926,530	\$192,844,826	3.88%
2010	\$5,098,146,876	\$197,126,947	3.87%
2011	\$5,058,104,978	\$195,529,112	3.87%
2012	\$5,066,969,036	\$208,070,156	4.11%
2013	\$4,787,897,881	\$185,134,664	3.87%
2014	\$4,932,807,990	\$203,716,485	4.13%
2015	\$4,951,675,428	\$205,060,620	4.14%
2016	\$5,206,169,249	\$206,767,589	3.97%
2017	\$5,636,393,224	\$220,273,687	3.91%
2018	\$5,937,729,104	\$302,325,670	5.09%
Total	\$56,470,372,448	\$2,306,522,130	4.08%

About the NCI Funded Research Portfolio (<https://fundedresearch.cancer.gov/nciportfolio/>)

The NCI Funded Research Portfolio (NFRP) web site contains information about research grants, contract awards, and intramural research projects funded by the National Cancer Institute. The NFRP provides access to various NCI budget reports that contain information about research funding according to specific research categories. It also provides the ability to search the data base in various ways, including text searching of project abstracts and the ability to search the NIH research categories that are assigned to projects carried out by extramural and intramural groups. ^(7D)

How does NCI generate NFRP funding data?

At the close of each fiscal year, NCI asks each of its scientific organizations to report their research funding according to specific research categories. The reports that NCI intramural and extramural programs provide are then combined to determine the NCI funding totals for individual research areas. The total research funding for each category is reviewed and verified before NCI publishes on the NCI web site, **Cancer.gov**. ^(7D) Unfortunately, the present Research Portfolio only has been completed through 2018. By now, it should have been completed through 2020. NCI stated they were working on it.

What is scientific coding?

Scientific coding refers to the categorization of research projects according to scientific focus. In this process, research projects are analyzed and classified according to scientific topic and content. Scientific coding allows the development of science-based budget information, which can be used in portfolio analysis to examine the distribution of funds across research areas. Scientific coding is also necessary to answer inquiries about the scientific and budgetary aspects of Institute-funded research. NCI employs a sophisticated system of scientific coding in which trained professionals and/or scientific staff analyze grant applications, contracts, and intramural projects to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site (SITE) codes. This coding structure is meant to describe in a consistent way the major scientific disciplines requested by NIH, DHHS, Congress, and the public. A critical characteristic of coded data is comparability from one fiscal year to the next. This process allows the Institute to respond quickly to requests for information from NCI staff and the broader community. The coding definitions used by the NCI intramural program are consistent with those used for extramural grants and research and development (R&D) contracts to maintain accuracy across the Institute's portfolio. ^(7D)

- Another report, preferred by OAR, is the NIH RePORTER, which is a congressionally mandated system all NIH Institutes and Centers (ICs) use to report data by fiscal year (FY). This tool highlights annual support for various research, condition, and disease categories (RCDC) based on grants, contracts, and other funding mechanisms *used across* NIH.

**NIH RePORT Categorical Spending
(RCDC)
NCI – Pediatric Cancer Category**

Fiscal Year	NCI Pediatric Cancer \$ Amount	Total NCI Obligations	% of Total Obligations
2016	\$289,845,271	\$5,206,169,272	5.57%
2017	\$351,782,326	\$5,636,392,678	6.24%
2018	\$413,099,150	\$5,927,729,104	6.97%
2019	\$437,681,409	\$5,992,439,908	7.30%
2020	\$502,159,184	\$6,383,348,911	7.87%
2021	\$565,721,399	\$6,442,735,236	8.78%

According to OAR, like the NFRP, the NIH RePORTER also does not account for the totality of NCI's investment in a given area of research because basic science awards cannot be categorized by individual cancer type. Using Total NCI Obligations, without making allowances for NIH items included in the Pediatric Cancer Amount, would distort the percentage of Total Obligations.

While both of the above reports, The NFRP and the NIH RePORTER, seem unable to capture a completely accurate measure of childhood cancer research expenditure as it relates to total research dollars, perhaps a better method to measure progress may be to compare NIH RePORTER pediatric dollars (c) to the Total NIH Dollars (d) for each fiscal year. This method would show changes from one year to the next. Note that the chart below shows that the pediatric cancer expenditures are growing from 2016 to 2021.

Fiscal Year	NCI ^(a) Funded Research Portfolio		NCI ^(b) Obligations	NIH ^(c) RePORTER			NIH ^(d) Obligations
	Dollars	% to NCI	Total Dollars	Dollars	% to NCI	% to NIH	Total Dollars
2016	\$206,767,589	3.97%	\$5,206,169,272	\$289,845,271	5.57%	0.90%	\$32.311 Billion
2017	\$220,273,687	3.91%	\$5,636,392,678	\$351,782,326	6.24%	1.03%	\$34.301 Billion
2018	\$302,325,670	5.09%	\$5,927,729,104	\$413,099,150	5.97%	1.11%	\$37.311 Billion
2019	Unavailable		\$5,992,439,908	\$437,681,409	7.30%	1.11%	\$39.313 Billion
2020	Unavailable		\$6,383,348,911	\$502,159,184	7.87%	1.20%	\$41.685 Billion
2021	Unavailable		\$6,442,735,236	\$565,721,399	8.78%	1.36%	\$41.664 Billion

a. NCI Funded Research Portfolio	https://fundedresearch.cancer.gov/nciportfolio/
b. NCI Obligations	https://www.cancer.gov/about-nci/budget/fact-book/archive
c. NIH RePORTER	https://projectreporter.nih.gov
d. NIH Obligations	https://www.everycrsreport.com/reports/R43341.html

Survival

- o The average 5-year survival rate for childhood cancer (0-19) as a whole is 86%. ^(1A)
- o Cancer survival rates vary not only depending upon the type of cancer, but also upon individual factors attributable to each child. ⁽⁶⁾
- o Five year survival rates can range from almost 0% for cancers such as DIPG (2.2%⁽⁴⁸⁾), a type of brain cancer, to over 90% for the most common type of childhood cancer known as Acute Lymphoma Leukemia (ALL). ⁽¹⁾
- o Diffuse intrinsic pontine glioma (DIPG) represents approximately 80% of the malignant brainstem tumors occurring in children. ⁽³⁴⁾
- o Despite numerous clinical trials, the outcome of children with DIPG continues to remain dismal, with a median survival of only 11 months, while only 10% of DIPG patients have \geq 2-year overall survival (OS) rate. ⁽⁴⁸⁾
- o 12.2% of all newly diagnosed brain tumors occur under age 20. ^(7G)
- o As of January 1, 2018 (the most recent date for which data exist), approximately 483,000 survivors of childhood and adolescent cancer (diagnosed at ages 0 to 19 years) were alive in the United States. ⁽³⁷⁾ The number of childhood cancer survivors was projected to grow to more than 500,000 by 2020. ⁽²⁷⁾
- o Approximately 1 in 530 young adults between the ages of ^[1]_{SEP} 20 and 39 is a survivor of childhood cancer. ⁽¹⁾

Pediatric Cancer 5-Year Ages 0 to19 for years 2011 through 2017: The table below is a representation of the estimated 5-year survival rates for various types of childhood cancers. It should be noted the survival rates listed below reflect general rates and in no way are a representation of an anticipated actual survival outcome for any individual child. ^(1A)

5-Year Relative Survival (2011 through 2017) ICCC Type, United States		Ages 0-19 *			
		Birth to 14 Years % of Cases Survival %	15 to 19 Years % of Cases Survival %		
All ICCC groups combined			85		86
Leukemias, myeloproliferative & myelodysplastic diseases		28	87	13	75
Lymphoid leukemia		21	92	7	76
Acute myeloid leukemia		4	68	3	67
Lymphomas and reticuloendothelial neoplasms		12	95	7	94
Hodgkin lymphoma		3	99	11	97
Non-Hodgkin lymphoma (including Burkitt lymphoma)		6	91	7	89
Central Nervous System neoplasms (a,d.)		26	74	21	76
Benign/borderline malignant tumors		8	97	13	98
Neuroblastoma & other peripheral nervous cell tumor		6	81	<1	66b
Retinoblastoma		2	96	<1	c
Nephroblastoma & other nonepithelial renal tumors		4	93	<1	c
Hepatic tumors		2	80	<1	56b
Hepatoblastoma		1	83	<1	c
Malignant bone tumors		4	73	5	68
Osteosarcoma		2	68	3	68
Ewing tumor & related bone sarcomas		1	76	2	59
Rhabdomyosarcoma		3	70	1	50b
Germ cell & gonadal tumors		3	90	10	93
Thyroid carcinoma		2	>99	12	>99
Malignant melanoma		1	96	3	95

*** Footnotes:**

Case Distribution (2014-2018) and 5-Year Relative Survival (2011-2017) by Age and International Classification of Childhood Cancer Type, Ages Birth to 19 Years, United States

Abbreviation: ICCC, International Classification of Childhood Cancer

Survival rates are adjusted for normal life expectancy and are based on follow-up of patients through 2018

a Benign and borderline brain tumors were excluded from survival calculations for overall central nervous system tumors and all cancers combined but were included in the denominator for case distribution.


b The standard error of the survival rate is between 5 and 10 percentage points.

c Statistic could not be calculated due to <25 cases during 2011 through 2017.

d. Includes Astrocytoma, Ependymoma, Medulloblastoma, Germ Cell, Brain Stem Glioma

(1a)

Mortality



- Cancer is the number one cause of death by disease among children.^(1A) Cancer alone represents nearly half of the top seven causes of death by disease in children aged 0-19 yrs. ⁽³⁵⁾
- 1,050 children (aged 0 -14) and 550 adolescents (aged 15-19) are expected to die from cancer in 2022 (excluding benign and borderline malignant brain tumors). ^(1A)
- Brain cancer represents 29.9% of total childhood cancer deaths while leukemia accounts for 24.9%^(7E)
- 1/3 of childhood brain and CNS cancers occur among those aged 5-9, median age at death is age 9. ⁽⁷ⁱ⁾
- On average, about 14% of children die within 5 years of diagnosis. Among those children who survive to five years from diagnosis, 18% of them will die over the next 25 years. ⁽⁸⁾
- From 1997 through 2017, overall cancer deaths among children ages 0 to 4 years decreased an average of 1.4% per year. The group of 5 to 9 years old decreased 1.1%, while 10 to 14 years old dropped 1.2%. Among adolescent ages 15 to 19 years, overall cancer death rates decreased the most at an average of 1.7% per year. ⁽³⁷⁾
- The most common causes of death in childhood cancer survivors are: The primary cancer comes back. A second (different) primary cancer forms. Heart and lung damage. ⁽⁵⁰⁾
- Those that survive the five years have an eight times greater mortality rate due to the increased risk of liver and heart disease and increased risk for recurrence of the original cancer or of a secondary cancer. ⁽⁸⁾
- There are 70 potential life years lost on average when a child dies of cancer ^(7b) compared to 14 potential life years lost for adults. ⁽¹³⁾
- Worldwide, cancer kills more than 100,000 children every year. ^(33A)

Drug Development

- Between the years of 2009 and 2019, nine of the 11 drugs used to treat acute lymphoblastic leukemia — which is the most common childhood cancer — were in and out of shortage. ⁽³²⁾
- While more than 200 cancer drugs have been developed and approved for adults⁽⁵⁸⁾ the FDA, through 2021 has approved a total of 35 drugs for use in the treatment of childhood cancers. 29 of the drugs were originally approved only for adult use. Today we have only six drugs that were approved in the first instance for use in cancer treatment for children: Teniposide (1992 for ALL) use now discontinued by NCI, clofarabine (2004 for ALL), dinutuximab (2015 for NB), tisagenlecleucel (2017 for ALL), calaspargase pegol-mk (2018 for ALL), selumetinib (2020 for NF1) and naxitamab (2020 for NB). ⁽⁷⁾
- The median lag time from first-in-human to first-in-child trials of oncology agents that were ultimately approved by FDA was 6.5 years. ⁽⁶¹⁾

- The FDA awarded Priority Review Vouchers (PRV) for four of the six drugs originally approved in the first instance for cancer treatment for children. PRV's are transferable and are desired incentives for developers of drugs for rare pediatric diseases. Holders of a PRV get a faster FDA drug approval process for a future drug of their choice. The vouchers are transferable and may be sold or traded. (42)

FDA Approved Drugs for Childhood Cancers **Highlighted drugs below** were approved in the first instance for use in cancer treatment for children

FDA Approved Drugs For Childhood Cancers *						updated 01/11/2022
Drug	Approved for	Type	Original Approval	Pediatric Approval	Indication	
Methotrexate	Adults/Peds	Chemo	8/10/1959	****	ALL	
Cyclophosphamide	Adults/Peds	Chemo	11/16/1959	****	Leukemia, lymphoma, NBL, retinoblastoma	♥
Vincristine	Adults/Peds	Chemo	7/10/1963	****	ALL, AML, Non-Hodgkin Lymphoma, rhabdomyosarcoma, NB	
Cytarabine	Adults/Peds	Chemo	6/17/1969	****	ALL, CML	
Procarbazine	Adults/Peds	Chemo	7/22/1969	****	Hodgkin lymphoma	
Doxorubicin	Adults/Peds	Chemo	8/7/1974	****	Wilms Tumor & other kidney cancers	♥
*FDAMA, enacted Nov. 21, 1997, amended the Federal Food, Drug, and Cosmetic Act relating to the regulation of food, drugs, devices, and biological products						
Daunorubicin	Adults/Peds	Chemo	12/19/1979	1/30/1998	ALL	♥
Pegaspargase	Peds/AYA	NME**	2/2/1994	4/24/2006	ALL	*ct
Asparaginase Erwinia	Adults/Peds	NME**	11/18/2011	11/18/2011	ALL, Non-Hodgkin Lymphoma	*ct
Everolimus	Adults/Peds	Chemo	10/29/2010	9/25/2012	SEGA / subependymal giant cell astrocytoma.	
Dactinomycin	Adults/Peds	Chemo	12/10/1964	8/23/2013	Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor	
Mercaptopurine	Adults/Peds	Chemo	9/11/1953	4/28/2014	ALL	
Dinutuximab	*PRV Pediatrics	NME**	3/10/2015	3/10/2015	High risk NB See *NB basic research note below	*ct
				3/14/2017	Micosatellite instability-high (MSI-H) or	
				5/23/2017	mismatch repair deficient solid tumor	
				6/13/2018	Adult and pediatric patients with refractory primary mediastinal largeB-cell lymphoma	
Pembrolizumab (Keytruda)	Adults/Peds	MAB***	9/4/2014	12/19/2018	MatatasticMerkel cell carcinoma(>12years)	*ct
				6/6/2020	Tumor mutational burden-high (TMB) solid tumors	
				10/14/2020	Relapsed or refractory classical Hodgkin lymphoma (cHL) Wilms Tumor	
Avelumab	Adults/Peds	MAB***	3/23/2017	3/23/2017	MatatasticMerkel cell carcinoma(>12years)	
Blinatumomab	Adults/Peds	MAB***	7/12/2017	7/12/2017	B-cell acute lymphoblastic leukemia	
Ipilimumab	Adults/Peds	MAB***	3/25/2010	7/21/2017	Unresectable or metastatic melanoma ≥ 12 yrs	
Tisagenlecleucel	*PRV Pediatrics	NME**	8/30/2017	8/30/2017	Relapsed or refractory ALL	*ct
Clofarabine	Pediatrics	NME**	12/28/2004	9/1/2017	Refactory ALL	*ct
Nelarabine	Adults/Peds	NME**	10/28/2005	9/1/2017	T-cell ALL, Non Hodgkin lymphoma	*ct
Dasatinib	Adults/Peds	Targeted Therapy	6/28/2006	11/9/2017	Ph+CML in the chronic phase,	
				12/21/2018	Ph+ALL,	*ct
Imatinib	Adults/Peds	Targeted	9/27/2006	11/9/2017	PH+ ALL and PH+ CML	*ct
Nilotinib	Adults/Peds	Targeted	10/29/2007	3/22/2018	Ph+CML in the chronic phase	
Nivolumab	12 yrs or old	MAB***	7/11/2018	7/11/2018	Mismatch repair-deficient and microsatellite instability-high colorectal cancer	
Iobenguane I 131	12 yrs or older		7/30/2018	7/30/2018	malignant pheochromocytoma paraganglioma	
Larotrectinib	Adults/Peds	NME**	11/26/2018	11/26/2018	Solid tumor with (NTRK) gene fusion	*ct
Calaspargase Pegol-mknl	1mo -21 yrs.	Multi-Agent Component	12/20/2018	12/20/2018	ALL Used with combination chemotherapy	*ct
Tagraxofusp-erzs	Adults/Peds	Targeted	12/21/2018	12/21/2018	Blastic plasmacytoid dendritic cell neoplasm	
entrectinib	Adults/Peds	Targeted	8/15/2019	8/15/2019	12 years or older to treat solid tumors that have certain changes in a gene called NTRK	
tazemetostat hydrobromide	Adults/Peds		1/23/2020	1/23/2020	epithelioid sarcoma 16 years and older whose cancer cannot be removed by surgery.	
selumetinib sulfate*PRV	Pediatrics	Targeted	4/10/2020	4/10/2020	2 yrs and older who have plexiform neurofibromas	
Gemtuzumab	Adults/Peds	MAB***	5/17/2000	6/16/2020	1 mo. & older Relapsed or refractory CD33+AML	
naxitamab	*PRV Pediatrics	MAB***	11/25/2020	11/25/2020	1 yr & older with certain types of high-risk neuroblastoma	
crizotinib	Peds/AYA	Targeted	3/11/2016	1/14/2021	1 yr. & Young Adult ALK-positive systemic anaplastic large cell lymphoma	
rituximab	Adults/Peds	MAB***	11/26/1997	12/2/2021	ALL, AML, Non-Hodgkin Lymphoma (in Combo with chemo)	

* Source: <https://www.cancer.gov/about-cancer/treatment/drugs/childhood-cancer-fda-approved-drugs>

*ct = Data from NCI-sponsored clinical trials were used to support the approval *PRV = Priority Review Voucher issued ** NME = New Molecular Entities

*** MAB = Monoclonal Antibody ****Exact pediatric-specific approval date is unknown.

*PRV = Priority Review Voucher issued ♥ Possible late-onset cardiotoxicity <https://www.uspharmacist.com/article/chemotherapy-agents-that-cause-cardiotoxicity>

*NB Dinutuximab - NCI basic research 1960-2015 <https://www.cancer.gov/research/areas/childhood/childhood-cancer-basic-cancer-research>

Drugs listed below are not cancer drugs, but are used to treat toxicity with treatments.


Information Below Supplied by the FDA:

Supportive Care Oncology Drugs to treat pediatric patients with toxicity associated with cancer treatment

Drug	Approved for	Type	Original Approval	Pediatric Approval	Indication
Pegfilgrastim	Adults/Peds		1/31/2002	11/13/2015	Decrease incidence of infection, increases survival in patients acutely exposed to myelosuppressive doses of radiation
Rasburicase	Adults/Peds	NME*	7/12/2002	7/12/2002	Management of plasma uric acid levels in patients at risk for tumor lysis syndrome
Palifermin	Adults/Peds		12/15/2004		Decreased incidence and duration of severe oral mucositis
Levofolacovorin	Adults/Peds		3/7/2008	3/7/2008	Rescue after HD-MTX
Tocilizumab	Adults/Peds	MAB***	1/8/2010	8/30/2017	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome
Voraxaze	Adults/Peds		1/17/2012	1/17/2012	Treatment of toxic plasma methotrexate concentration based on delayed MTX clearance

Global Facts

Global Facts



Each year, an estimated 400,000 children and adolescents of 0-19 years old develop cancer. (30b, 44) Cancer kills more than 100,000 children each year. (33A)

Globally, in 2017, there were 11.2 million Years of Life Lost due to childhood cancer. (3)

The most common types of childhood cancers include leukemias, brain cancers, lymphomas and solid tumors, such as neuroblastoma and Wilms tumors. (30b)

In high-income countries, where comprehensive services are generally accessible, more than 80% of children with cancer are cured*. In low- and middle-income countries (LMICs), less than 30% are cured*. (30b) *The term "cured" equals "survived 5 years past diagnosis."

Globally in 2017, childhood cancer was the sixth leading cause of total cancer burden globally and the ninth leading cause of childhood disease burden globally. (3)

More than 90% of children at risk of developing childhood cancer each year live in low-income and middle-income countries (LMICs). (3)

Avoidable deaths from childhood cancers in LMICs result from lack of diagnosis, misdiagnosis or delayed diagnosis, obstacles to accessing care, abandonment of treatment, death from toxicity, and relapse. (30b)

Nearly one in two children with cancer are never diagnosed and may die untreated. (31)

Global 5-year net childhood cancer survival is currently estimated for diagnosed cases at 37.4%. (46) 100,000 children will lose their lives every year. (33a)

Children with cancer in low and middle-income countries are four times more likely to die of the disease (cancer) than children in high-income countries. (30a)

- In 2018, The World Health Organization (WHO) launched the Global Initiative for Childhood Cancer with partners to provide leadership and technical assistance to support governments in building and sustaining high-quality childhood cancer programs. The goal is to achieve at least 60% survival rate globally by 2030, for all children with cancer. This represents an approximate doubling of the current cure rate and will save an additional one million lives over the next decade. The objectives are to increase capacity of countries to deliver best practices in childhood cancer care and also to prioritize childhood cancer and increase available funding at the national and global levels. (30)

- Some cancers are more prevalent in developing countries. For example, Burkitt's lymphoma is more common in East and West Africa with over 4,000 cases in East Africa and over 10,000 in West Africa while only around 20 were recorded in the UK in 2015. ⁽³⁰⁾
- Because most of the world's population is NOT covered by cancer surveillance systems or vital registration found in developed countries, and in addition, childhood cancer is rare and often presents with non-specific symptoms that mimic those of more prevalent infectious and nutritional conditions found in many low income developing countries. Worldwide/UN-regional cancer incidence is therefore estimated using a Baseline Model (BM) method to quantify the cancer burden in children. It is estimated that there will be 13.7 million cases of childhood cancer between 2020-2050. Unless there are major improvements in diagnosis and treatments, of this, 45% will go undiagnosed and 11.1 million will die if no further investments in interventions are made. The vast majority, almost 85%, will be concentrated in developing countries. ^(33A)

Psychosocial Care ⁽²⁰⁾

- Childhood cancer threatens every aspect of the family's life and the possibility of a future, which is why optimal cancer treatment must include psychosocial care. ¹¹
- The provision of psychosocial care has been shown to yield better management of common disease-related symptoms and adverse effects of treatment such as pain and fatigue. ¹²
- Depression and other psychosocial concerns can affect adherence to treatment regimens by impairing cognition, weakening motivation, and decreasing coping abilities. ¹³
- For children and families, treating the pain, symptoms, and stress of cancer enhances quality of life and is as important as treating the disease. ¹⁴
- Childhood cancer survivors reported higher rates of pain, fatigue, and sleep difficulties compared with siblings and peers, all of which are associated with poorer quality of life. ¹⁵
- Changes in routines disrupt day-to-day functioning of siblings. ¹⁶ Siblings of children with cancer are at risk for emotional and behavioral difficulties, such as anxiety, depression, and post traumatic stress disorder. ¹⁷
- Symptoms of posttraumatic stress disorder are well documented for parents whose children have completed cancer treatment. ¹⁸
- Chronic grief has been associated with many psychological (e.g., depression and anxiety) and somatic symptoms (e.g., loss of appetite, sleep disturbances, fatigue), including increased mortality risk. ¹⁹
- Cancer survivors in the United States reported medication use for anxiety and depression at rates nearly two times those reported by the general public, likely a reflection of greater emotional and physical burdens from cancer or its treatment. ²¹
- Financial hardship during childhood cancer has been found to affect a significant proportion of the population and to negatively impact family wellbeing. ²²
- Adolescents with cancer experienced significantly more Health Related Hindrance (HRH) of personal goals than healthy peers, and their HRH was significantly associated with poorer health-related quality of life, negative affect, and depressive symptoms. ²³
- Peer relationships of siblings of children with cancer are similar to classmates, though they experience small reductions in activity participation and school performance. ²⁴
- Chronic health conditions resulting from childhood cancer therapies contribute to emotional distress in adult survivors. ²⁵
- Parents have been found to report significant worsening of all their own health behaviors, including poorer diet and nutrition, decreased physical activity, and less time spent engaged in enjoyable activities 6 to 18 months following their child's diagnosis. ²⁶

Prevention

- Childhood cancer is fundamentally different to adult cancer in its biology, clinical classification, and treatment. Most childhood cancers are not caused by modifiable risk factors, public health campaigns would not have a large effect on decreasing their incidence ⁽⁵⁶⁾
- Intake of vitamins and folate supplementation during the preconception period or pregnancy has been demonstrated to have a protective effect. ⁽⁵⁵⁾

- Exposures to pesticides, tobacco smoke, solvents, and traffic emissions have consistently demonstrated positive associations with the risk of developing childhood leukemia. ⁽⁵³⁾
- The U.S. Environmental Protection Agency (EPA) reports that 75 percent of U.S. households used at least one pesticide product indoors during the past year. The EPA also states, “Exposure to pesticides may result in irritation to eye, nose and throat, damage to central nervous system, kidney and increased risk of cancer.” ⁽⁵²⁾
- Researchers found a higher level of common household pesticides in the urine of children with acute lymphoblastic leukemia. The findings should not be seen as cause-and-effect, but suggests an association between pesticide exposure and development of childhood ALL. ⁽⁵⁹⁾
- Exposure to toxic substances, such as industrial chemicals and radiation, can increase the risk of leukemia. People may encounter radiation during imaging tests such as MRI scans, X-rays, and CT scans. ⁽⁵⁷⁾
- Since children are more radiosensitive than adults and although CT scans are very useful clinically, potential cancer risks exist from associated ionizing radiation. ⁽⁵⁴⁾
- Exposure of parents to ionizing radiation is also a possible concern in terms of the development of cancer in their future offspring. Children whose mothers had x-rays during pregnancy (that is children who were exposed before birth) and children exposed after birth to diagnostic medical radiation from computed tomography (CT) scans have been found to have a slight increase in risk of leukemia and brain tumors and possible other cancers. ⁽³⁷⁾
- Risk of childhood leukemia was associated with higher crop area near mother’s homes during pregnancy; CNS tumors were associated with higher cattle density. ⁽⁵¹⁾
- In a study of 1.3 million children aged under 19 years of age, childhood phthalate exposure was associated with incidence of osteosarcoma and lymphoma. ^(60, 60A)

Factors Affecting Access to Follow-up Care

Stakeholders GAO interviewed and studies GAO reviewed identified three factors that affect access to follow-up care for childhood cancer survivors—individuals of any age who were diagnosed with cancer from ages 0 through 19. These factors are care affordability, survivors' and health care providers' knowledge of appropriate care, and proximity to care. Childhood cancer survivors need access to follow-up care over time for serious health effects known as late effects—such as developmental problems, heart conditions, and subsequent cancers—which result from their original cancer and its treatment.

- **Affordability:** Survivors of childhood cancer may have difficulty paying for follow-up care, which can affect their access to this care. For example, one study found that survivors were significantly more likely to have difficulty paying medical bills and delay medical care due to affordability concerns when compared to individuals with no history of cancer.
- **Knowledge:** Survivors' access to appropriate follow-up care for late effects of childhood cancer can depend on both survivors' and providers' knowledge about such care, which can affect access in various ways, according to stakeholders GAO interviewed and studies GAO reviewed: ⁽⁴³⁾
 - Some survivors may have been treated for cancer at an early age and may have limited awareness of the need for follow-up care.
 - Some primary or specialty care providers may not be knowledgeable about guidelines for appropriate follow-up care, which can affect whether a survivor receives recommended treatment. Follow-up care may include psychosocial care (e.g., counseling), and palliative care (e.g., pain management).
- **Proximity:** Survivors may have difficulty reaching appropriate care settings. Stakeholders GAO interviewed and studies GAO reviewed noted that childhood cancer survivors may have to travel long distances to receive follow-up care from multidisciplinary outpatient clinics—referred to as childhood cancer survivorship clinics. The lack of proximity may make it particularly difficult for survivors with limited financial resources to adhere to recommended follow-up care.

Endnotes

- 1 American Cancer Society, Childhood and Adolescent Cancer Statistics, 2014
<https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2014/special-section-cancer-in-children-and-adolescents-cancer-facts-and-figures-2014.pdf>
- 1a Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2022. *CA: A Cancer Journal for Clinicians* 2022;
<https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21708>
- 2 St. Jude Children’s Research Hospital, (JAMA. 2013;309 [22]: 2371-2381)
<http://jama.jamanetwork.com/article.aspx?articleid=1696100>
- 3 Lancet Oncology, Sep 2019 Volume 20 Number 9 p1211– p1225, “The global burden of childhood and adolescent cancer in 2017”
[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(19\)30339-0/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30339-0/fulltext)
- 4 National Vital Statistics Report, vol. 62.6, November 4, 2021
<http://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet>
- 5 Agency for Healthcare Research and Quality, US Dept. of Health & Human Services, “Pediatric Cancer Hospitalizations 2009, May 2012, Rebecca Anhang Price, Ph.D., Elizabeth Stranges, M.S., and Anne Elixhauser, Ph.D.”
<https://www.hcup-us.ahrq.gov/reports/statbriefs/sb132.jsp>
- 6 American Society of Clinical Oncology
<http://jco.ascopubs.org/content/28/15/2625.short>
- 6A American Society of Clinical Oncology (ASCO) 12/2020
<https://www.cancer.net/cancer-types/childhood-cancer/introduction>
- 7 National Cancer Institute, <http://www.cancer.gov/research/areas/childhood>
https://www.cancer.gov/research/areas/childhood/fda-approved-drugs-childhood-cancers?cid=eb_govdel
- 7A National Cancer Institute, “Age and Cancer Risk” 3/05/2021. Source: SEER 21 2013–2017, all races, both sexes.
<https://www.cancer.gov/about-cancer/causes-prevention/risk/age>
- 7B National Cancer Institute, SEER Cancer Statistics Review 1973-1997 (NCI 2000)
<http://jnci.oxfordjournals.org/content/93/5/341.full>
- 7C National Cancer Institute, NIH/NCI
<https://fundedresearch.cancer.gov/nciportfolio/>
- 7D National Cancer Institute, NIH/NCI
<https://fundedresearch.cancer.gov/nciportfolio/about.jsp>
- 7E Centers for Disease Control and Prevention, NCHS Data Brief No. 257, September 2016, “Declines in Cancer Death Rates Among Children and Adolescents in the United States, 1999-2014”
<https://www.cdc.gov/nchs/products/databriefs/db257.htm>
- 7G National Cancer Institute, Percent of New Cases by Age Group: Brain and Other Nervous System Cancer SEER 21 2012-2016, All Races, Both Sexes,
- 7H National Cancer Institute, Pediatric Supportive Care (PDQ®)–Patient Version
<https://www.cancer.gov/types/childhood-cancers/pediatric-care-pdq>
- 7i National Cancer Institute, SEER Percent of Deaths by Age, All races, Both Sexes
http://seer.cancer.gov/csr/2014_2018/results_merged/topic_med_age.pdf
- 8 Journal of the National Cancer Institute “Cause-Specific Late Mortality Among 5 Year Survivors”
<http://jnci.oxfordjournals.org/content/100/19/1368.full>
- 9 Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2018/, based on November 2020 SEER data submission, posted to the SEER web site, April 2021.
- 10 Additional information in this statement was obtained from several reliable and authoritative sources
- 11 Institute of Medicine, 2008 - Cancer Care for the Whole Patient

- 12 Jacobsen et al., 2012 (Journal of Clinical Oncology, 30 (11), p.1151-1153)
- 13 National Center for Health Statistics (NCHS): National Vital Statistics System (NVSS) "Provisional Life Expectancy Estimates for January through June, 2020, Report #10, Feb. 2021
<https://www.cdc.gov/nchs/data/vsrr/VSRR10-508.pdf>
- 14 Institute of Medicine 2015 - Comprehensive Care for Children with Cancer and Their Families
- 15 Children's Oncology Group Long Term Follow-Up Guidelines, 2013
- 16 Alderfer et al., 2010 (Psycho-oncology, 19 (8), p. 789-805)
- 17 Alderfer et al., 2003 (Journal of Pediatric Psychology, 28 (4), p. 281-286)
- 18 Kazak et al., 2004 (Journal of Pediatric Psychology, 29 (3), p. 211-219)
- 19 Alam et al., 2012 (Death Studies, 36 (1), p. 1-22)
- 20 Psychosocial care addresses the effects that cancer treatment has on the mental health and emotional wellbeing of patients, their family members, and their professional caregivers. A single profession alone does not provide psychosocial care: Instead, every patient-healthcare provider interaction provides an opportunity to assess the stressors and concerns of children and their family members.
- 21 Hawkins et al., 2017 (Journal of Clinical Oncology, 5 (1), 78-87)
- 22 Bona et al., 2014 (Journal of Pain Symptom Management, 47 (3), 594-600)
- 23 Schwartz & Brumley, 2017 (Journal of Adolescent & Young Adult Oncology, 6 (1), 142-149)
- 24 Alderfer et al., 2015 (Journal of Pediatric Psychology, 40 (3) 309-319)
- 25 Vuotto et al., 2017 (Cancer, 123 (3), 521-528)
- 26 Wiener et al., 2016 (Journal of Pediatric Oncology Nursing, 33(5), 378-386)
- 27 Robison LL, Hudson MM. Survivors of childhood & adolescent cancer: life long risks & responsibilities. Nat Rev Cancer 2014; 14:6170
NCI <https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet>
- 28 UChicagoMedicine Understanding risks for childhood cancer survivors
<https://www.uchicagomedicine.org/forefront/cancer-articles/understanding-risks-for-childhood-cancer-survivors>
- 29 Kebudi, R. and F.B. Cakir, Management of Diffuse Pontine Gliomas in Children: Recent Developments. Pediatric Drugs, 2013. 15(5): 351-362
- 30 World Health Organization <https://www.who.int/news-room/fact-sheets/detail/cancer-in-children>
- 30A World Health Organization <https://www.who.int/cancer/childhood-cancer/en/>
- 30b World Health Organization 2021 Dec. 13, "Childhood Cancer: Key Facts,"
<https://www.who.int/news-room/fact-sheets/detail/cancer-in-children>
- 31 The Lancet. Science Daily, 26 February 2019. www.sciencedaily.com/releases/2019/02/190226184140.htm.
- 32 FDA Report Drug Shortages
<https://www.fda.gov/drugs/drug-shortages/report-drug-shortages-root-causes-and-potential-solutions>
- 33 Lancet Oncology. 2015 Mar; 16(3): e123-e136. doi: 10.1016/S1470-2045(14)70409-7
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485458/>
- 33A Lancet Oncology. "Sustainable care for children with cancer." 03/30/2020
<https://www.thelancet.com/commissions/childhood-cancer>

- 34 Effect of Time from Diagnosis to Start of Radiotherapy on Children with Diffuse Intrinsic Pontine Glioma
2014 Jan 30. doi: 10.1002/pbc.24971 PMID: PMC4378861NIHMSID: NIHMS667729 PMID: 24482196
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378861/>
- 35 Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2019 on CDC WONDER Online Database, released in 2020. Data are from the Multiple Cause of Death Files, 1999-2019, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. <http://wonder.cdc.gov/ucd-icd10.html>
- 36 The National Children's Cancer Society, The Economic Impact of Childhood Cancer, November 30, 2018
Retrieved from <https://policycommons.net/artifacts/1647909/the-economic-impact-of-childhood-cancer/> on 16Dec 2021. CID:20.500.12592/qp3g3v.
- 36a Household income and risk-of-poverty of parents of long-term childhood cancer survivors, Pediatric Blood Cancer, 2017 Aug;64(8).doi: 10.1002/pbc.26456. Epub 2017 Mar 6. <https://pubmed.ncbi.nlm.nih.gov/28266129/>
- 37 The National Cancer Institute "Cancer in Children and Adolescents" 11/04/2021
<https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet>
- 38 American Cancer Society, Treatment and Survivorship Statistics, 2019
<https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21565>
- 39 National Cancer Institute, NIH/NCI **Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version**
Updated 9/21/2021 https://www.cancer.gov/types/childhood-cancers/late-effects-pdq#_417
- 40 National Cancer Institute, Cancer Stat Facts: Cancer Among Adolescents and Young Adults (AYAs) (Ages 15–39)
<https://seer.cancer.gov/statfacts/html/aya.html>
- 41 U.S. News & World Reports "Childhood Cancer Survivors Still Face Shorter Life Expectancy," January 2,2020
<https://www.usnews.com/news/healthiest-communities/articles/2020-01-02/life-expectancy-for-childhood-cancer-survivors-has-improved-study-says>
- 42 Food and Drug Administration, FDA, 12,27,2020, Rare Pediatric Disease (RPD) Designation and Voucher Programs
<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/rare-pediatric-disease-rpd-designation-and-voucher-programs>
- 43 United States Government Accounting Offices, GAO-20-636R, Jul 31, 2020. "Survivors of Childhood Cancer: Factors Affecting Access to Follow-up Care" <https://www.gao.gov/products/gao-20-636r>
- 44 Cancer Epidemiology, "Childhood cancer: Estimating regional and global incidence," Volume 71, Part B, April 2021, 101662, Used 3.4 2015 Global Childhood Cancer (GCC) Model
<https://www.sciencedirect.com/science/article/pii/S1877782119301729>
- 45 NIH/National Cancer Institute, Age-Adjusted and Age-Specific SEER Cancer Incidence Rates, 2014-2018, Table 2.1
https://seer.cancer.gov/csr/1975_2018/results_single/sect_02_table.01_2pgs.pdf
- 45A NIH/National Cancer Institute, Age-Adjusted and Age-Specific SEER Cancer Incidence Rates, 2014-2018, Table 2.4

https://seer.cancer.gov/csr/1975_2018/results_single/sect_02_table.01_2pgs.pdf

- 46 Lancet Oncology, Volume 20, Issue 7, July 2019, Pages 972-983, "Global childhood cancer survival estimates and priority- setting: a simulation-based analysis,"
<https://www.sciencedirect.com/science/article/abs/pii/S1470204519302736>
- 47 Cancer Epidemiology Biomarkers, 1 August 2021, DOI:10.1158/1055-9965.EPI-21-0154
<https://aacrjournals.org/cebp/article-abstract/30/8/1536/670996/Longitudinal-Evaluation-of-Neuromuscular>
- 48 Hofmann et al. (J Clin Oncol, 2018 vol. 36(19) pp. 1963-1972)
<https://pubmed.ncbi.nlm.nih.gov/29746225/>
- 49 National Cancer Institute Illustration by Cristiana Couciero May 16, 2016
- 50 The National Cancer Institute "Late Effects of Treatment for Childhood Cancer" 9/21/2021
<https://www.cancer.gov/types/childhood-cancers/late-effects-pdq>
- 51 Residential proximity to agriculture and risk of childhood leukemia and central nervous system tumors in the Danish national birth cohort. <https://pubmed.ncbi.nlm.nih.gov/32711331/>
- 52 US Environmental Protection Agency. Pesticides and Child Safety. Washington, DC: US Environmental Protection Agency; "Pesticides' Impact on Indoor Air Quality,"
<https://www.epa.gov/indoor-air-quality-iaq/pesticides-impact-indoor-air-quality>
- 53 Science Digest. "Current Problems in Pediatric and Adolescent Health Care," Volume 46, Issue 10, October 2016, Pages 317-352, <https://www.sciencedirect.com/science/article/pii/S1538544216300694>
- 54 Lancet. 2012 Aug 4;380(9840):499-505. doi: 10.1016/S0140-6736(12)60815-0.Epub 2012 Jun 7. "**Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study**,"PubMed <https://pubmed.ncbi.nlm.nih.gov/22681860/>
- 55 American Academy of Pediatrics, "Childhood Leukemia: A Preventable Disease," Volume 138, Issue Supplement_1, November 2016, https://publications.aap.org/pediatrics/article-abstract/138/Supplement_1/S45/34075/Childhood-Leukemia-A-Preventable-Disease
- 56 The Lancet. 4/1/2020 Volume 21Number 4, p.489, "Sustainable care for indigenous children with cancer."
[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(20\)30137-6/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30137-6/fulltext)
- 57 Medical News Today, "Is leukemia hereditary?" by Jamie Eske, May 30, 2019
<https://www.medicalnewstoday.com/articles/325332>
- 58 JAMA Network 3/15/2022 Volume 5 Number 3, doi:10.1001/jamanetworkopen.2022.2265. "Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021," David J. Benjamin, MD; Alexander Xu, BA; Mark P. Lythgoe, MBBS; et al
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2790102>
- 59 Georgetown University Medical Center "Common Household Pesticides Linked To Childhood Cancer Cases In Washington Area": August 4, 2009, <https://www.sciencedaily.com/releases/2009/07/090728102306.htm>
- 60 CTVNews-HEALTH News, 3/18/2022, "Exposure to 'everyday chemical' associated with higher incidence of childhood cancer: study, Journal of the National Cancer Institute 2/18/2022:
<https://pubmed.ncbi.nlm.nih.gov/35179607/>
- 61 European Journal of Cancer, Volume 112 pg 49-56, May 1, 2019, "Timing of first-in-child trials of FDA-approved oncology drugs." Dylan V, Neel, David S. Shulman, Steven G. DuBois. Published March 28, 2019, DOI:
<https://doi.org/10.1016/j.ejca.2019.02.011>

THIS DOCUMENT IS NOT INTENDED TO OFFER SPECIFIC STATISTICS REGARDING AN INDIVIDUAL PATIENT OR THE PATIENT'S SPECIFIC FORM OF CANCER AND IS NOT A SUBSTITUTE FOR INFORMATION THAT MAY BE SOUGHT FROM A PHYSICIAN. IT IS MERELY INTENDED, BASED ON INFORMATION PRESENTLY AVAILABLE TO THE AUTHORS, TO BE A GOOD FAITH GENERAL PRESENTATION OF CHILDHOOD CANCER STATISTICS THAT MAY BE HELPFUL TO OTHERS SEEKING SUCH GENERAL INFORMATION.

March 31, 2022